Sign in or create an account to add this stock to your watchlist.
About UroGen Pharma (NASDAQ:URGN)
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy. The company is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat various forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Ra'anana, Israel.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:URGN
CUSIPN/A
Phone972-9770-7601
Debt
Debt-to-Equity RatioN/A
Current Ratio23.28
Quick Ratio23.22
Price-To-Earnings
Trailing P/E Ratio-28.20
Forward P/E Ratio-17.28
P/E GrowthN/A
Sales & Book Value
Annual Sales$8.16 million
Price / Sales101.91
Cash FlowN/A
Price / CashN/A
Book Value$9.01 per share
Price / Book6.71
Profitability
EPS (Most Recent Fiscal Year)($2.14)
Net Income$-20,000,000.00
Net MarginsN/A
Return on Equity-35.54%
Return on Assets-33.35%
Miscellaneous
Employees33
Outstanding Shares13,750,000
UroGen Pharma (NASDAQ:URGN) Frequently Asked Questions
What is UroGen Pharma's stock symbol?
UroGen Pharma trades on the NASDAQ under the ticker symbol "URGN."
How were UroGen Pharma's earnings last quarter?
UroGen Pharma (NASDAQ:URGN) announced its quarterly earnings results on Tuesday, May, 15th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.73) by $0.15. The business had revenue of $0.48 million for the quarter. View UroGen Pharma's Earnings History.
When is UroGen Pharma's next earnings date?
What price target have analysts set for URGN?
7 brokers have issued 1-year target prices for UroGen Pharma's stock. Their predictions range from $25.00 to $75.00. On average, they anticipate UroGen Pharma's stock price to reach $50.60 in the next year. View Analyst Ratings for UroGen Pharma.
What are Wall Street analysts saying about UroGen Pharma stock?
Here are some recent quotes from research analysts about UroGen Pharma stock:
- 1. According to Zacks Investment Research, "UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel. " (5/15/2018)
- 2. Cowen Inc analysts commented, "URGN presented updates for MitoGel’s Phase 3 OLYMPUS trial (topline data in 2Q18)." (11/15/2017)
Who are some of UroGen Pharma's key competitors?
Some companies that are related to UroGen Pharma include Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Tesaro (TSRO), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS), Emergent Biosolutions (EBS), Horizon Pharma (HZNP), Evotec A.G. (EVTCY), Global Blood Therapeutics (GBT), The Medicines (MDCO) and Arena Pharmaceuticals (ARNA).
Who are UroGen Pharma's key executives?
UroGen Pharma's management team includes the folowing people:
- Mr. Ron Bentsur, CEO & Director (Age 52)
- Mr. Gary S. Titus, CFO & Principal Accounting Officer (Age 58)
- Mr. Stephen Mullennix, Chief Operating Officer
- Ms. Catherine Bechtold, Director of Corp. Communications and Investor Relations
- Ms. Christine Cassiano, Corp. Affairs Officer
When did UroGen Pharma IPO?
(URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.
Has UroGen Pharma been receiving favorable news coverage?
Media coverage about URGN stock has been trending somewhat positive on Thursday, according to Accern Sentiment. The research group scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. UroGen Pharma earned a news sentiment score of 0.22 on Accern's scale. They also gave news coverage about the company an impact score of 46.82 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are UroGen Pharma's major shareholders?
UroGen Pharma's stock is owned by a number of of institutional and retail investors. Top institutional investors include ARKIN MOSHE (9.37%), Clal Insurance Enterprises Holdings Ltd (2.06%), Millennium Management LLC (1.16%), Citadel Advisors LLC (0.59%), Lyon Street Capital LLC (0.24%) and Barclays PLC (0.18%). View Institutional Ownership Trends for UroGen Pharma.
Which institutional investors are selling UroGen Pharma stock?
Which institutional investors are buying UroGen Pharma stock?
URGN stock was purchased by a variety of institutional investors in the last quarter, including Clal Insurance Enterprises Holdings Ltd, Millennium Management LLC, Citadel Advisors LLC, Barclays PLC, Alps Advisors Inc., DAFNA Capital Management LLC, Quantbot Technologies LP and ETF Managers Group LLC. View Insider Buying and Selling for UroGen Pharma.
How do I buy shares of UroGen Pharma?
Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is UroGen Pharma's stock price today?
One share of URGN stock can currently be purchased for approximately $60.48.
How big of a company is UroGen Pharma?
UroGen Pharma has a market capitalization of $851.07 million and generates $8.16 million in revenue each year. The company earns $-20,000,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. UroGen Pharma employs 33 workers across the globe.
How can I contact UroGen Pharma?
UroGen Pharma's mailing address is 9 HaTaasiya St, Raanana L3, 4365007. The company can be reached via phone at 972-9770-7601 or via email at [email protected]
MarketBeat Community Rating for UroGen Pharma (URGN)
MarketBeat's community ratings are surveys of what our community members think about UroGen Pharma and other stocks. Vote "Outperform" if you believe URGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe URGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
UroGen Pharma (NASDAQ:URGN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for UroGen Pharma in the last 12 months. Their average twelve-month price target is $50.60, suggesting that the stock has a possible downside of 16.34%. The high price target for URGN is $75.00 and the low price target for URGN is $25.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 2.71 | 2.67 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $50.60 | $50.60 | $42.80 | $41.00 |
| Price Target Upside: | 16.34% downside | 15.38% downside | 15.02% upside | 1.35% downside |
UroGen Pharma (NASDAQ:URGN) Consensus Price Target History
UroGen Pharma (NASDAQ:URGN) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
UroGen Pharma (NASDAQ:URGN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
UroGen Pharma (NASDAQ URGN) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 67.39%
UroGen Pharma (NASDAQ URGN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/28/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 209,298 | $40.60 | $8,497,498.80 | |  |
(Data available from 1/1/2013 forward)
UroGen Pharma (NASDAQ URGN) News Headlines
| Source: |
|
UroGen Pharma (NASDAQ:URGN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
UroGen Pharma (NASDAQ:URGN) Income Statement, Balance Sheet and Cash Flow Statement
UroGen Pharma (NASDAQ URGN) Stock Chart for Thursday, May, 24, 2018
Loading chart…
